VIDEO: Aflibercept 8 mg has ‘excellent’ outcomes with extended dosing intervals in DME
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Sean D. Adrean, MD, discusses data on aflibercept 8 mg vs. aflibercept 2 mg for the treatment of diabetic macular edema at 1 year.
The post hoc analysis used data from the phase 2/3 PHOTON trial and investigated the impact of each aflibercept dose on vision and central retinal thickness in patients with a baseline best corrected visual acuity of 20/50 or worse or 20/40 or better.
“It was excellent to see that patients with the 8 mg aflibercept were able to go and maintain these longer extended dosing intervals also while maintaining excellent visual and central retinal thickness outcomes,” Adrean said.
Collapse
Adrean SD. Outcomes of patients with diabetic macular edema (DME) and baseline best-corrected visual acuity (BCVA) of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg: a post hoc analysis of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about
Click Here to Manage Email Alerts